Chemotherapeutic complete remission in patients with metastatic ovarian dysgerminoma: Potential for cure and preservation of reproductive capacity

David M. Gershenson, J. Taylor Wharton, Richard C. Kline, Dale M. Larson, John J. Kavanagh, Felix N. Rutledge

Research output: Contribution to journalArticlepeer-review

52 Scopus citations

Abstract

Two patients with metastatic dysgerminoma of the ovary were treated with a combination of etoposide, bleomycin, and cisplatin at The University of Texas M. D. Anderson Hospital and Tumor Institute at Houston. Both patients achieved a complete remission. Patient 1 developed a massive recurrence in the para‐aortic lymph nodes 21 months after diagnosis and treatment with right salpingo‐oophorectomy alone. She received four cycles of chemotherapy and is free of disease 21 months from the start of chemotherapy. Patient 2 had Stage III dysgerminoma and a lymphangiogram positive for tumor in the para‐aortic lymph nodes. After surgery she received three cycles of chemotherapy and is free of disease 20 months from the start of chemotherapy. Both complete remissions were documented with second‐look laparotomy. Chemotherapy may be an alternative to radiotherapy for the treatment of metastatic dysgerminoma and should also be considered for selected patients with Stage I disease. A literature review further supports the conclusion that additional clinical trials might expand the indications for chemotherapy in patients with this disease.

Original languageEnglish (US)
Pages (from-to)2594-2599
Number of pages6
JournalCancer
Volume58
Issue number12
DOIs
StatePublished - Dec 15 1986

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Chemotherapeutic complete remission in patients with metastatic ovarian dysgerminoma: Potential for cure and preservation of reproductive capacity'. Together they form a unique fingerprint.

Cite this